In vitro antiamyloidogenic properties of 1,4-naphthoquinones

Biochemical and Biophysical Research Communications

Volumn 400, Issue 1, 2010, Pages 169-174

  Bermejo Bescós, Paloma ^a   Martín Aragón, Sagrario ^a   Jiménez Aliaga, Karim L ^a   Ortega, Andrea ^a   Molina, María Teresa ^b   Buxaderas, Eduardo ^c   Orellana, Guillermo ^c   Csákÿ, Aurelio G ^c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Secretase (BACE); 1,4 Naphthoquinones; A fibrils; Alzheimer's disease; Amyloid aggregation

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 3 (4 HYDROXYPHENYL) 5 METHOXY 1,4 NAPTHTHOQUINONE; AMYLOID; BETA SECRETASE; BETA SECRETASE INHIBITOR; JUGLONE; UNCLASSIFIED DRUG; 1,4-NAPHTHOQUINONE; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; NAPHTHOQUINONE; PROTEINASE INHIBITOR; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; NEUROTOXICITY; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; METABOLISM; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; CELL LINE, TUMOR; HUMANS; NAPHTHOQUINONES; PROTEASE INHIBITORS;

EID: 79953282113     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.038     Document Type: Article

References (36)

1. Tauraite D., Razumas V., Butkus E. Lipophilic 1,4-naphthoquinone derivatives: synthesis and redox properties in solution and entrapped in the aqueous cubic liquid-crystalline phase of monoolein. Chem. Phys. Lipids 2009, 159:45-50.
2. Valderrama J.A., Colonelli P., Vasquez D., Gonzalez M.F., Rodriguez J.A., Theoduloz C. Studies on quinones. Part 44: novel angucyclinone N-heterocyclic analogues endowed with antitumoral activity. Bioorg. Med. Chem. 2008, 16:10172-10181.
3. Montenegro R.C., Araujo A.J., Molina M.T., Marinho Filho J.D., Rocha D.D., Lopez-Montero E., Goulart M.O., Bento E.S., Alves A.P., Pessoa C., de Moraes M.O., Costa-Lotufo L.V. Cytotoxic activity of naphthoquinones with special emphasis on juglone and its 5-O-methyl derivative. Chem. Biol. Interact. 2010, 184:439-448.
4. Hadden M.K., Hill S.A., Davenport J., Matts R.L., Blagg B.S. Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorg. Med. Chem. 2009, 17:634-640.
5. Turbyville T.J., Wijeratne E.M., Liu M.X., Burns A.M., Seliga C.J., Luevano L.A., David C.L., Faeth S.H., Whitesell L., Gunatilaka A.A. Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. J. Nat. Prod. 2006, 69:178-184.
6. Dou F., Netzer W.J., Tanemura K., Li F., Hartl F.U., Takashima A., Gouras G.K., Greengard P., Xu H. Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA 2003, 100:721-726.
7. Shen H.Y., He J.C., Wang Y., Huang Q.Y., Chen J.F. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J. Biol. Chem. 2005, 280:39962-39969.
8. Sundriyal S., Viswanad B., Ramarao P., Chakraborti A.K., Bharatam P.V. New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies. Bioorg. Med. Chem. Lett. 2008, 18:4959-4962.
9. Zhao X., Ou Z., Grotta J.C., Waxham N., Aronowski J. Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res. 2006, 1073-1074:460-469.
10. Son T.G., Camandola S., Arumugam T.V., Cutler R.G., Telljohann R.S., Mughal M.R., Moore T.A., Luo W., Yu Q.S., Johnson D.A., Johnson J.A., Greig N.H., Mattson M.P. Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J. Neurochem. 2010, 112:1316-1326.
11. Nam K.N., Son M.S., Park J.H., Lee E.H. Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications. Neuropharmacology 2008, 55:819-825.
12. Castagnoli K.P., Steyn S.J., Petzer J.P., Van der Schyf C.J., Castagnoli N. Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco. Chem. Res. Toxicol. 2001, 14:523-527.
13. Thijssen H.H., Drittij-Reijnders M.J. Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4. Br. J. Nutr. 1996, 75:121-127.
14. Li J., Wang H., Rosenberg P.A. Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes. J. Neurosci. Res. 2009, 87:1997-2005.
15. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
16. De Strooper B., Umans L., Van Leuven F., Van Den Berghe H. Study of the synthesis and secretion of normal and artificial mutants of murine amyloid precursor protein (APP): cleavage of APP occurs in a late compartment of the default secretion pathway. J. Cell Biol. 1993, 121:295-304.
17. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
18. Forloni G., Colombo L., Girola L., Tagliavini F., Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001, 487:404-407.
19. Kim H., Park B.S., Lee K.G., Choi C.Y., Jang S.S., Kim Y.H., Lee S.E. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J. Agric. Food Chem. 2005, 53:8537-8541.
20. Salloway S., Mintzer J., Weiner M.F., Cummings J.L. Disease-modifying therapies in Alzheimer's disease. Alzheimers Demen. 2008, 4:65-79.
21. Kelly T.R., Parekh N.D., Trachtenberg E.N. Regiochemical control in the Diels-Alder reaction of substituted naphthoquinones. The directing effects of C-6 oxygen substitutents. J. Organic Chem. 1982, 47:5009-5013.
22. Van T.N., De Kimpe N. Synthesis of 6H-naphtho[2,3-c]chromene-7,12-diones via palladium-catalyzed intramolecular cyclization of 2-bromo-3-aryloxymethyl-1,4-naphthoquinones. Tetrahedron 2003, 59:5941-5946.
23. Tietze L.F., Singidi R.R., Gericke K.M. Total synthesis of the proposed structure of the anthrapyran metabolite delta-indomycinone. Chem.-Eur. J. 2007, 13:9939-9947.
24. Maugel N., Snider B.B. Efficient synthesis of the tetracyclic aminoquinone moiety of marmycin A. Org. Lett. 2009, 11:4926-4929.
25. Molina M.T., Navarro C., Moreno A., Csaky A.G. Arylation of benzo-fused 1,4-quinones by the addition of boronic acids under dicationic Pd(II)-catalysis. Org. Lett. 2009, 11:4938-4941.
26. Maillard M.C., Hom R.K., Benson T.E., Moon J.B., Mamo S., Bienkowski M., Tomasselli A.G., Woods D.D., Prince D.B., Paddock D.J., Emmons T.L., Tucker J.A., Dappen M.S., Brogley L., Thorsett E.D., Jewett N., Sinha S., John V. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. J. Med. Chem. 2007, 50:776-781.
27. Hom R.K., Gailunas A.F., Mamo S., Fang L.Y., Tung J.S., Walker D.E., Davis D., Thorsett E.D., Jewett N.E., Moon J.B., John V. Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase. J. Med. Chem. 2004, 47:158-164.
28. Al-Majed A.A., Al-Omar F.A., Nagi M.N. Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur. J. Pharmacol. 2006, 543:40-47.
29. Yang X., Dai G., Li G., Yang E.S. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 2010, 41:110-113.
30. Z. Mei, B. Situ, X. Tan, S. Zheng, F. Zhang, P. Yan, and P. Liu, Cryptotanshinone upregulates alpha-secretase by activation PI3K pathway in cortical neurons. Brain Res. June 2 (2010) [Epub ahead of print].
31. Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. USA 2001, 98:5815-5820.
32. von Arnim C.A., von Einem B., Weber P., Wagner M., Schwanzar D., Spoelgen R., Strauss W.L., Schneckenburger H. Impact of cholesterol level upon APP and BACE proximity and APP cleavage. Biochem. Biophys. Res. Commun. 2008, 370:207-212.
33. Tamagno E., Bardini P., Obbili A., Vitali A., Borghi R., Zaccheo D., Pronzato M.A., Danni O., Smith M.A., Perry G., Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 2002, 10:279-288.
34. Apelt J., Bigl M., Wunderlich P., Schliebs R. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int. J. Dev. Neurosci. 2004, 22:475-484.
35. Sugie S., Okamoto K., Rahman K.M., Tanaka T., Kawai K., Yamahara J., Mori H. Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett. 1998, 127:177-183.
36. Calabrese V., Cornelius C., Mancuso C., Pennisi G., Calafato S., Bellia F., Bates T.E., Giuffrida Stella A.M., Schapira T., Dinkova Kostova A.T., Rizzarelli E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem. Res. 2008, 33:2444-2471.